Invesaro

Stocks Health care GTHP

OTC · Health care

Guided Therapeutics Inc (GTHP)

Guided Therapeutics Inc brought in $650K of revenue over the twelve months to June 30, 2026, up 450.8% from a year earlier. It posted a net loss of $3.1M. In fiscal 2025 capital spending exceeded operating cash flow by $1.1M. At June 30, 2026 it held $12K in cash against $53K of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.

Watch GTHP in 60 seconds
Price
$0.18
-27.42% on the day · September 28, 2026
52-week range $0.15 to $0.54
Market cap
$17.4M
Revenue (last 12 months)
$650K
+450.8% year on year
Net margin
-471.2%

What Guided Therapeutics Inc does

Guided Therapeutics Inc is registered with the SEC under industry code SIC 3845 (Electromedical & Electrotherapeutic Apparatus). Its shares trade on OTC under the ticker GTHP.

Revenue and profit by year

Revenue
FY18: $57K $57K FY18FY19: $36K $36K FY19FY20: $102K $102K FY20FY21: $81K $81K FY21FY22: $13K $13K FY22FY23: $98K $98K FY23FY24: $7K $7K FY24FY25: $767K $767K FY25
Net income
FY18: $1M $1M FY18FY19: -$1.9M -$1.9M FY19FY20: -$279K -$279K FY20FY21: -$2.1M -$2.1M FY21FY22: -$4.3M -$4.3M FY22FY23: -$3.5M -$3.5M FY23FY24: -$2.4M -$2.4M FY24FY25: -$3.2M -$3.2M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$767K-$2.4M-$3.2M-$0.04-$1.1M
2024$7K-$2.1M-$2.4M-$0.05-$1.1M
2023$98K-$3.5M-$3.5M-$0.07-$1.7M
2022$13K-$3.3M-$4.3M-$0.15-$1.5M
2021$81K-$2.4M-$2.1M-$0.18-$1.6M
2020$102K-$1.1M-$279K-$0.04-$1.9M

Full financial statements: income, balance sheet and cash flow

Next report expected around November 12, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 13, 2025. Not a date the company has announced. See the report calendar

Where GTHP ranks in Health care

Revenue$767K
#657 of 742 in Health care · Bottom 11%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Guided Therapeutics Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. August 13, 2026
    Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.01 versus -$0.01.
  2. May 15, 2026
    Quarterly report 10-Q · period to March 31, 2026Diluted EPS -$0.01 versus -$0.01.
  3. March 31, 2026
    Annual report 10-K · period to December 31, 2025Revenue rose 10,857% to $767K versus the prior year; diluted EPS -$0.04 versus -$0.05.
  4. March 10, 2026
  5. November 13, 2025
    Quarterly report 10-Q · period to September 30, 2025Revenue was $60K; diluted EPS -$0.01 versus -$0.01.
  6. August 14, 2025
    Quarterly report 10-Q · period to June 30, 2025Revenue was $117K; diluted EPS was -$0.01.
  7. May 15, 2025
    Quarterly report 10-Q · period to March 31, 2025Diluted EPS was -$0.01.
  8. March 31, 2025
    Annual report 10-K · period to December 31, 2024Revenue fell 93% to $7K versus the prior year; diluted EPS -$0.05 versus -$0.07.
  9. December 23, 2024
  10. November 14, 2024

Recent insider filings (Forms 3, 4 and 144): 10, the latest on May 5, 2026. Insider transactions on SEC

Insider trades

What the people running Guided Therapeutics Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

Bought (open market)
$0
last 90 days
Sold
$0
last 90 days
DateInsiderWhatSharesPriceValueFiling
March 31, 2026 Imhoff John EDirector, 10% owner Exercised options 157,417 $0.07 $11K Form 4
March 26, 2026 Blumberg Richard P.Director, 10% owner Other change 56,093 - - Form 4
March 26, 2026 Blumberg Richard P.Director, 10% owner Other change 260 - - Form 4
March 26, 2026 Blumberg Richard P.Director, 10% owner Other change 1,040,000 - - Form 4
March 26, 2026 Blumberg Richard P.Director, 10% owner Other change 19,038 - - Form 4
March 26, 2026 Blumberg Richard P.Director, 10% owner Other change 88 - - Form 4
March 26, 2026 Blumberg Richard P.Director, 10% owner Other change 352,000 - - Form 4
March 26, 2026 Imhoff John EDirector, 10% owner Other change 2,157 - - Form 4
March 26, 2026 Imhoff John EDirector, 10% owner Other change 10 - - Form 4
March 26, 2026 Imhoff John EDirector, 10% owner Other change 40,000 - - Form 4
February 27, 2026 Imhoff John EDirector, 10% owner Other change 100 - - Form 4
February 27, 2026 Imhoff John EDirector, 10% owner Other change 400,000 - - Form 4
February 27, 2026 Imhoff John EDirector, 10% owner Exercised options 156,086 $0.07 $10.9K Form 4
February 25, 2026 Blumberg Richard P.Director, 10% owner Exercised options 1,000,000 - - Form 4
February 25, 2026 Imhoff John EDirector, 10% owner Exercised options 500,000 - - Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns GTHP

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

We have not read this company's Schedule 13D and 13G filings yet.

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

3 insiders reported holding 32,297,479 shares in total, about $5.8M at the last price.

HolderSharesAs of
Imhoff John EDirector, 10% owner 21,252,673 March 31, 2026
Blumberg Richard P.Director, 10% owner 10,391,311 March 26, 2026
James Michael CDirector 653,495 February 25, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about GTHP

What does Guided Therapeutics Inc do?

Guided Therapeutics Inc is registered with the SEC under industry code SIC 3845 (Electromedical & Electrotherapeutic Apparatus). Its shares trade on OTC under the ticker GTHP.

Is Guided Therapeutics Inc profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $3.1M on revenue of $650K.

How much revenue does Guided Therapeutics Inc make?

Over the twelve months to June 30, 2026 Guided Therapeutics Inc reported revenue of $650K. That is 450.8% more than a year earlier.

When did Guided Therapeutics Inc last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026.

Similar companies

Compare GTHP with

Compare GTHP with any company

Follow GTHP

Get an email when Guided Therapeutics Inc files with the SEC: results, executive changes, material agreements and annual reports.

Follow GTHP: get an email when it files

Where the numbers come from

Financial figures are the values Guided Therapeutics Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.